DMRA

Damora Therapeutics Inc

21.50

Nov 02 • 3:03 PM ET +0.01 (0.06%)

Healthcare Biotechnology USA Small NASD

Peers: GERN SNDX KURA AGIO IRON SLS COAG KROS BLSM PRLD

| Held by: IWM XBI VXF IWO VTWO SCHA IWN ITOT VTWG SCHB

Index	RUT
Market Cap	1.33B
Enterprise Value	917.00M
Income	-262.83M
Sales	0.00M
Book/sh	6.25
Cash/sh	8.76
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	7
IPO	Oct 29, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.44
P/C	2.46
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	19.73
Current Ratio	19.73
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-124.78
EPS next Y	-2.11
EPS next Q	-0.48
EPS this Y	48.78%
EPS next Y	-3.49%
EPS next 5Y	13.54%
EPS past 3/5Y	-36.14% -34.72%
Sales past 3/5Y	- -
EPS Y/Y TTM	-850.33%
Sales Y/Y TTM	-
EPS Q/Q	80.38%
Sales Q/Q	-
Earnings	Aug 10 AMC
EPS/Sales Surpr.	0.00% -

Insider Own	22.08%
Insider Trans	0.09%
Inst Own	88.20%
Inst Trans	17.55%
ROA	-94.32%
ROE	-100.00%
ROIC	-50.93%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	4.90%
SMA50	-7.89%
SMA200	-16.15%
Trades

Shs Outstand	61.73M
Shs Float	48.12M
Short Float	10.71%
Short Ratio	9.86
Short Interest	5.15M
52W High	38.33 -43.89%
52W Low	4.95 334.41%
Volatility	7.63% 7.49%
ATR (14)	1.51
RSI (14)	49.92
Beta	1.53
Rel Volume	0.64
Avg Volume	522.73K
Volume	288,954

Perf Week	1.14%
Perf Month	4.13%
Perf Quarter	-28.37%
Perf Half Y	-17.07%
Perf YTD	-6.55%
Perf Year	193.76%
Perf 3Y	59.25%
Perf 5Y	-75.00%
Perf 10Y	-
Recom	1.00
Target Price	46.89
Prev Close	21.49
Price	21.50
Change %	0.06%

Consensus

Strong Buy

Avg. Price Target

$46.89

Implied Upside

+118.1%

Analysts12incl. previous ratings

Rating Distribution12 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jul 27, 2026	Initiated	JJefferies	Buy	$50	+132.5%
Jun 11, 2026	Initiated	HH.C. Wainwright	Buy	$45	+109.3%
Jun 08, 2026	Initiated	TTD Cowen	Buy
May 28, 2026	Initiated	WWedbush	Outperform	$35	+62.8%
Apr 24, 2026	Initiated	RRBC Capital Mkts	Outperform	$40	+86.0%
Mar 25, 2026	Initiated	EEvercore ISI	Outperform	$46	+113.9%
Feb 17, 2026	Initiated	UUBS	Buy	$45	+109.3%
Jan 07, 2026	Initiated	LLeerink Partners	Outperform	$46	+113.9%
Dec 01, 2025	Initiated	GGuggenheim	Buy	$32	+48.8%
Apr 26, 2021	Resumed	CCredit Suisse	Outperform	$12	-44.2%
Nov 23, 2020	Initiated	SSVB Leerink	Outperform	$27	+25.6%
Nov 23, 2020	Initiated	CCredit Suisse	Outperform	$29	+34.9%
Nov 23, 2020	Initiated	BBofA Securities	Buy	$21	-2.3%

Oct-02-26 07:59AM	Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-03-26 08:00AM	Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-10-26 04:05PM	Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-05-26 08:00AM	Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis (GlobeNewswire)
Aug-03-26 04:01PM	Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.11%
08:00AM	Loading…
Jul-17-26 08:00AM	Damora Announces Redomestication from Delaware to Cayman Islands (GlobeNewswire)
Jul-01-26 04:01PM	Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.67%
Jun-01-26 08:00AM	Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-12-26 04:05PM	Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire) -5.21%
May-01-26 08:00AM	Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-30-26 08:00AM	Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-23-26 08:00AM	Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors (GlobeNewswire) +27.07%
Mar-19-26 04:10PM	Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire) -9.22% -5.52%
Mar-09-26 08:00AM	Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders (GlobeNewswire)
Mar-04-26 08:00AM	Galecto Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.70%
08:00AM	Loading…
Mar-02-26 08:00AM	Galecto to Participate in Leerink Partners 2026 Global Healthcare Conference (GlobeNewswire)
Feb-12-26 04:01PM	Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million (GlobeNewswire) +37.75%
Feb-10-26 10:42PM	Galecto Announces Pricing of $275 Million Underwritten Public Offering (GlobeNewswire) -10.33%
04:04PM	Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock (GlobeNewswire)
Jan-12-26 08:00AM	Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones (GlobeNewswire) +6.44%
Jan-07-26 09:41AM	Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls (The Fly)
Jan-06-26 08:00AM	Galecto Announces Key Additions to Leadership Team (GlobeNewswire)
Dec-16-25 05:00PM	Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.06% -12.23%
Nov-12-25 05:20AM	Metagenomi, Ovid CEOs step aside; Cogent soars on unprecedented stomach cancer data (BioPharma Dive)
Nov-10-25 04:05PM	This Penny Stock Just Quadrupled. Should You Buy It Now? (Barchart) +248.48% +36.70%
07:00AM	Galecto Announces Acquisition of Damora Therapeutics (GlobeNewswire)
Nov-06-25 04:30PM	Galecto Reports Third Quarter 2025 Operating and Financial Results (GlobeNewswire) -14.95%
Nov-03-25 09:00AM	Galecto to Highlight GB3226 Program at ASH 2025 (GlobeNewswire) -8.47%
Oct-07-25 04:43PM	This Penny Stock Just Jumped 750%. Can It Retain These Gains for the Long Term? (Barchart) +383.02% -40.57%
Aug-05-25 04:15PM	Galecto Reports Second Quarter 2025 Operating and Financial Results (GlobeNewswire)
04:30PM	Loading…
May-08-25 04:30PM	Galecto Reports First Quarter 2025 Operating and Financial Results (GlobeNewswire) +5.15%
Mar-19-25 04:45PM	Galecto Reports Full-Year 2024 Financial Results (GlobeNewswire)
Feb-06-25 08:00AM	Galecto to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-14-24 09:55AM	Galecto (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-01-24 08:30AM	Galecto Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-18-24 08:15AM	Galecto price target raised to $10 from $9 at Oppenheimer (TipRanks) +5.79%
Oct-15-24 08:30AM	Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler (GlobeNewswire)
Oct-07-24 08:45AM	Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines (GlobeNewswire) -27.53%
Aug-28-24 09:00AM	Galecto Announces Reverse Stock Split (GlobeNewswire) -6.59%
Aug-12-24 10:53PM	GLTO Stock Earnings: Galecto Beats EPS for Q2 2024 (InvestorPlace) +6.26%
May-03-24 10:54AM	GLTO Stock Earnings: Galecto Beats EPS for Q1 2024 (InvestorPlace)
May-01-24 04:01PM	Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab (GlobeNewswire) +5.43%
Mar-15-24 01:53PM	GLTO Stock Earnings: Galecto Beats EPS for Q4 2023 (InvestorPlace) +5.30%
Feb-14-24 12:00PM	Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) +11.93%
Jan-09-24 04:57PM	What Makes Galecto, Inc. (GLTO) a New Strong Buy Stock (Zacks)
Dec-22-23 06:52AM	Galecto posts myelofibrosis data as search for savior continues, investors shrug (FierceBiotech.com)
Dec-21-23 04:05PM	Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis (GlobeNewswire)
Oct-23-23 08:00AM	Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial (GlobeNewswire)
Sep-28-23 09:49AM	Spotify downgraded, Tractor Supply upgraded: Wall Street's top analyst calls (The Fly)
Sep-27-23 05:08AM	Galecto lays off 70%, hunts for 'strategic alternatives' in wake of fibrosis drug fail (FierceBiotech.com) +22.24%
Sep-26-23 04:01PM	Galecto Announces Plans to Explore Strategic Alternatives (GlobeNewswire)
Aug-31-23 11:00AM	Galecto to Present at Investor Conferences in September (GlobeNewswire)
Aug-17-23 07:01PM	OrbiMed Advisors LLC Reduces Stake in Galecto Inc (GuruFocus.com) -7.34%
08:58AM	Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More (Zacks)
Aug-16-23 07:46AM	Galecto (GLTO) Down 71% as Lung Disease Candidate Fails (Zacks)
Aug-15-23 07:35AM	Galecto to discontinue development of lung disease treatment (Reuters) -71.22%
07:30AM	Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Jul-31-23 04:05PM	Galecto Reports Second Quarter Operating and Financial Results (GlobeNewswire) -9.09%
Jul-27-23 11:02PM	ORBIMED ADVISORS LLC Reduces Stake in Galecto Inc (GuruFocus.com)
Jul-25-23 09:59AM	These 2 Strong Buy Penny Stocks Could Go Boom, Say Analysts (TipRanks) +29.79%
Jun-20-23 08:58AM	Galecto Set to Join Russell Microcap® Index (GlobeNewswire)
May-30-23 08:00AM	Galecto to Present at the Upcoming Jefferies Healthcare Conference (GlobeNewswire)
May-23-23 08:30AM	Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis (GlobeNewswire)
May-20-23 08:54AM	Companies Like Galecto (NASDAQ:GLTO) Could Be Quite Risky (Simply Wall St.)
May-17-23 04:01PM	Galecto to Present Poster at Upcoming ATS 2023 International Conference (GlobeNewswire) +5.86%
Apr-28-23 08:00AM	Galecto Reports First Quarter Operating and Financial Results (GlobeNewswire)
Apr-13-23 08:30AM	Galecto to Present Two Posters at AACR Annual Meeting 2023 (GlobeNewswire)
Mar-09-23 07:00AM	Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022 (GlobeNewswire) -8.13%
Mar-02-23 04:05PM	Galecto to Participate in Oppenheimers 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-01-23 08:00AM	Galecto to Participate in SVB Securities Global Biopharma Conference (GlobeNewswire) +5.65%
Dec-11-22 07:36AM	Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth? (Simply Wall St.)
Dec-07-22 04:05PM	Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-24-22 09:55AM	Galecto, Inc. (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-11-22 12:00PM	All You Need to Know About Galecto, Inc. (GLTO) Rating Upgrade to Strong Buy (Zacks)
Nov-08-22 09:15AM	Galecto Reports Third Quarter Operating and Financial Results (GlobeNewswire) -7.35%
06:00AM	Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients (GlobeNewswire)
Nov-03-22 08:00AM	Galecto to Participate in Jefferies London Healthcare Conference (GlobeNewswire) +20.01%
Oct-31-22 08:00AM	Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLDs The Liver Meeting® 2022 (GlobeNewswire) +6.35%
Oct-19-22 08:00AM	Galectos Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute (GlobeNewswire)
Oct-17-22 06:00AM	Galecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022 (GlobeNewswire)
Sep-29-22 11:17AM	Galecto's Myelofibrosis Candidate Reduces Bone Marrow Fibrosis (Benzinga) -22.08%
06:00AM	GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target (GlobeNewswire)
Sep-06-22 08:30AM	Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-29-22 08:30AM	Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal (GlobeNewswire)
Jul-29-22 09:00AM	Galecto Reports Second Quarter Operating and Financial Results (GlobeNewswire)
Jul-03-22 08:17AM	Will Galecto (NASDAQ:GLTO) Spend Its Cash Wisely? (Simply Wall St.)
Jun-16-22 08:00AM	Galecto Announces First Patient Enrolled in Phase 2 Trial of GB1211 in Combination with Atezolizumab for First-Line Treatment of NSCLC (GlobeNewswire)
May-31-22 08:30AM	Galecto to Participate at Jefferies Healthcare Conference (GlobeNewswire)
May-26-22 08:30AM	Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting (GlobeNewswire)
May-02-22 08:30AM	Galecto to Participate at Upcoming Investor Conferences (GlobeNewswire)
Apr-29-22 08:57AM	Galecto Reports First Quarter Operating and Financial Results (GlobeNewswire)
Apr-26-22 08:30AM	Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF (GlobeNewswire) -7.94%
Mar-29-22 08:30AM	Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis (GlobeNewswire)
Mar-25-22 10:25AM	UnitedHealth (UNH) Arm Optum Acquires Refresh Mental Health (Zacks)
Mar-15-22 11:10AM	Ensign Group (ENSG) Up 9.9% in 3 Months: More Room to Grow? (Zacks)
Mar-10-22 11:05AM	Here's Why You Should Retain Community Health (CYH) Stock (Zacks)
Mar-09-22 10:49AM	Anthem (ANTM) Rises 3.7% Since Q4 Earnings, Reiterates View (Zacks) +7.49%
Mar-04-22 10:00AM	Galecto, Inc. (GLTO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Feb-17-22 05:00PM	Galecto Reports Financial Results for the Year Ended December 31, 2021 (GlobeNewswire) -5.48% -5.29%
Feb-07-22 08:00AM	Galecto to Participate at Upcoming Investor Conferences (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jarrett Jennifer	Director, President and CEO	Sep 25 '26	Buy	20.23	12,500	252,875	512,500	Sep 28 07:00 AM
Firmani Lori	Officer	Aug 05 '26	Proposed Sale	31.10	1,800	55,980		Aug 06 11:34 AM
Winslow Garrett	General Counsel	Jul 06 '26	Sale	29.98	245	7,345	2,289	Jul 07 08:00 PM
Firmani Lori	Officer	Jun 22 '26	Proposed Sale	25.36	7,615	193,140		Jun 22 02:27 PM
Bruno Julianne	Director	Feb 09 '26	Option Exercise	0.00	129,000	0	137,032	Feb 12 06:05 AM
Fairmount Funds Management LLC	Director	Feb 09 '26	Option Exercise	0.00	8,713,000	0	5,809,000	Feb 12 06:03 AM
Schambye Hans T.	Chief Executive Officer	Jan 02 '26	Sale	21.38	700	14,966	4,682	Jan 06 04:30 PM
Winslow Garrett	General Counsel	Jan 02 '26	Sale	21.38	255	5,452	1,854	Jan 06 04:30 PM
Firmani Lori	Chief Financial Officer	Jan 02 '26	Sale	21.41	135	2,890	931	Jan 06 04:30 PM

Damora Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jorgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgard Schambye in 2011 and is headquartered in Waltham, MA.

Senior VPMr. Garrett Winslow Esq.

CEOMs. Jennifer A. Jarrett M.B.A.

Co-FounderMr. Ulf J. Nilsson Ph.D.

Ph.D.Dr. Hakon Leffler M.D.

FRCPProf. Tariq Sethi B.Sc.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DMRA

Damora Therapeutics Inc

Upgrade your Finviz experience